The Valley Desk

NCT03112603 · Interventional trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Overall registry status Completed

Phase 3

Conditions Graft-versus-host Disease (GVHD)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov